The US regulator has granted Priority Review to a submission from Regeneron Pharmaceuticals (Nasdaq: REGN) to offer REGN-EB3 for Ebola.
The investigational triple antibody treatment is supported by data from the PALM clinical trial, conducted in the Democratic Republic of Congo, which was stopped early due to efficacy.
In the study, Regeneron’s option was compared with ZMapp, another cocktail of three antibodies developed by Mapp Biopharmaceutical.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze